MDxHealth (NASDAQ:MDXH) Posts Earnings Results, Beats Expectations By $0.07 EPS

MDxHealth (NASDAQ:MDXH) announced its earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07, Zacks reports. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%.

MDxHealth Stock Performance

Shares of MDXH stock traded down $0.12 on Wednesday, hitting $1.83. 97,573 shares of the stock traded hands, compared to its average volume of 102,566. The company has a market capitalization of $86.54 million, a PE ratio of -1.20 and a beta of 1.34. The company’s fifty day moving average is $2.02 and its 200 day moving average is $2.20. MDxHealth has a 1-year low of $1.55 and a 1-year high of $3.85. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MDXH. Lake Street Capital started coverage on shares of MDxHealth in a research note on Thursday, October 31st. They issued a “buy” rating and a $7.00 price objective on the stock. Piper Sandler cut their target price on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.